Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-03-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于变更监事完成的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the change in the company's supervisory board member (监事). It details the election of a new non-employee representative supervisor and the resignation of the previous supervisor. There is no financial data, no mention of financial results, no report attached or referenced, and the document is relatively short (885 characters). The content clearly relates to changes in the company's board or supervisory personnel. Therefore, this fits the category of Board/Management Information (MANG).
2021-03-18 Chinese
关于部分首次公开发行股票募集资金专项账户销户完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the closure of certain special accounts for funds raised from the company's initial public offering (IPO). It details the management, usage, and changes related to the raised funds, including changes in fund usage, supervisory agreements, and account closures. The document references multiple prior announcements and approvals related to fundraising and fund management but does not contain financial statements or detailed financial performance data. The length is about 3,078 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on fundraising and capital management updates rather than earnings, audit, or governance reports. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2021-03-16 Chinese
关于变更部分首次公开发行股票募集资金用途以及更换保荐机构后重新签订募集资金三方监管协议以及变更部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding changes in the use of funds raised from its initial public offering (IPO) and the replacement of the sponsoring institution, along with the re-signing of a tripartite supervision agreement for the raised funds and changes to the special accounts for these funds. It details the approval of these changes by the board and shareholders, the amounts raised, the specific projects funded, and the regulatory compliance with Shenzhen Stock Exchange rules and China Securities Regulatory Commission approvals. The document is primarily about the management and regulatory oversight of IPO proceeds and related agreements, not a financial report or earnings release. It is a regulatory announcement about capital use and supervision, fitting the category of Capital/Financing Update (CAP). The document length is 4518 characters, which is substantial and contains detailed information about financing and capital management, not just a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2021-03-10 Chinese
关于公司部分董事、高级管理人员减持股份计划的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding a planned reduction in shareholding by certain directors and senior management of Zhejiang Tailin Biotechnology Co., Ltd. It details the shareholders involved, their shareholding percentages, the planned reduction quantities, reasons for reduction, and compliance with relevant regulations. The document does not contain financial statements, earnings data, or detailed management discussion. It is a notification about insider share transactions by company directors and executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is under 5,000 characters and is a standalone announcement, not a report or certification.
2021-03-08 Chinese
天健会计师事务所（特殊普通合伙）关于公司申请向不特定对象发行可转换公司债券的审核问询函中有关财务事项的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation and response to a regulatory inquiry (审核问询函) from the Shenzhen Stock Exchange regarding the financial matters of Zhejiang Tailin Biotechnology Co., Ltd. related to its application for issuing convertible bonds to unspecified investors. It includes extensive financial data, investment project details, capital expenditure breakdowns, depreciation policies, risk disclosures, and project profitability forecasts. The content focuses on the company's capital raising activities, use of proceeds, and financial projections tied to the convertible bond issuance. This is not a full annual or interim report, nor is it a simple announcement or certification. It is a regulatory response document related to capital raising and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2021-03-03 Chinese
上海市锦天城律师事务所关于公司向不特定对象发行可转换公司债券的补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding Zhejiang Tailin Biotechnology Co., Ltd.'s issuance of convertible bonds to unspecified investors. It includes legal analysis, compliance with securities laws, detailed explanations about land acquisition, permits, certificates, and financial forecasts related to the bond issuance. The document references regulatory inquiries from the Shenzhen Stock Exchange and discusses the company's financing arrangements and compliance with registration rules. It is a comprehensive legal opinion related to a capital raising activity (convertible bond issuance), not a general annual or quarterly report, earnings release, or management discussion. It is not a simple announcement or certification but a substantive legal opinion document. Therefore, the filing type corresponds to a Capital/Financing Update (CAP).
2021-03-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.